Core Viewpoint - The announcement highlights that Gaoshi Medical's subsidiary, Shenzhen Gaoshi Technology Co., Ltd., has received approval for its "Electrophysiological Examination System" from the Guangdong Provincial Drug Administration, marking a significant advancement in ophthalmic diagnostic tools [1][2]. Group 1: Product Features - The approved system includes three main functions: Visual Evoked Potential (VEP), Electroretinography (ERG), and Electrooculography (EOG) [1]. - VEP is primarily used for assessing the visual pathway function from the retinal ganglion cells to the visual cortex, serving as an objective monitoring tool for patients unable to cooperate with subjective vision tests [1]. - ERG evaluates retinal function, particularly in detecting retinal diseases, while EOG assesses the function of the retinal pigment epithelium and photoreceptors, aiding in the differentiation of diseases like retinitis pigmentosa [1]. Group 2: Clinical Applications - The Electrophysiological Examination System has become a routine examination method in ophthalmology, providing pathways for the diagnosis of fundus diseases and objective examination methods for retinal function and optic nerve lesions [2]. - The system's technology extracts specific electrophysiological signals from the visual system in response to optical stimuli, enabling accurate early diagnosis of ocular diseases [2]. - Its non-invasive, objective, quantitative, and repeatable characteristics make it significant for diagnosing and differentiating diseases, evaluating treatment efficacy, and objectively assessing visual function [2].

Core Viewpoint - The approval of the "Electrophysiological Examination System" by the Guangdong Provincial Drug Administration marks a significant advancement for the company in the ophthalmology medical device sector, enhancing diagnostic capabilities for eye diseases [1][2]. Company Summary - The company's subsidiary, Shenzhen Gaoshi Technology Co., Ltd., has received a medical device registration certificate for its electrophysiological examination system, which includes three main functions: Visual Evoked Potential (VEP), Electroretinography (ERG), and Electrooculography (EOG) [1]. - The VEP function is particularly useful for assessing the visual pathway from the retina to the visual cortex, serving as an objective monitoring tool for brain function in patients unable to cooperate with subjective vision tests [1]. - The ERG function evaluates retinal function and can be used to screen for retinal diseases, while the EOG assesses the function of the retinal pigment epithelium and photoreceptors, aiding in the differentiation of diseases like retinitis pigmentosa [1]. Industry Summary - The electrophysiological examination system has become a routine examination method in ophthalmology, providing pathways for the diagnosis of fundus diseases and offering objective examination methods for retinal function and optic nerve lesions [2]. - This system operates by extracting specific electrophysiological signals emitted by the visual system in response to optical stimuli, enabling accurate early diagnosis of eye diseases [2]. - The technology is characterized by its non-invasive, objective, quantitative, and repeatable nature, playing a crucial role in the diagnosis, differential diagnosis, and prognosis evaluation of eye diseases [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 眼電生理檢查系統獲得中國醫療器械註冊證 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司附屬公司深圳高視科技 有限公司（「高視科技」）之「眼電生理檢查系統」近日已獲得由廣東省藥品監督 管理局批准的醫療器械註冊證。 眼電生理檢查系統已成為眼科常規檢查手段之一，為眼底疾病檢查及診斷提 供了檢查途徑，同時為視網膜功能及視神經病變提供了客觀檢查手段。它是通 過對人體視覺系統在特定的光學信號刺激下發出的特定電生理信號的提取來 實現對眼科疾病準確的早期定位診斷，適用於視通路、視神經、視網膜的疾病 檢測。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | FF301 本月底法定 ...

Core Viewpoint - Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) significantly over the past trading days, indicating a potential shift in investor sentiment towards the company [1]. Group 1: Shareholding Changes - On October 14, southbound funds reduced their holdings by 16,300 shares, marking a decrease of 0.25% [2]. - Over the last five trading days, there has been a cumulative net reduction of 80,500 shares, with reductions occurring on all five days [1][2]. - In the last twenty trading days, the total net reduction reached 761,000 shares, with reductions on all twenty days [1]. Group 2: Current Holdings - As of the latest data, southbound funds hold 6,385,300 shares of Gaoshi Medical, which represents 4.31% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Gaoshi Medical Technology Co., Ltd. primarily engages in ophthalmic medical services and operates four divisions: self-owned products, distribution, technical services, and others [2]. - The company's products are widely used in various ophthalmic sub-specialties, including fundus diseases, cataracts, glaucoma, refraction, and pediatric ophthalmology [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 本月底法定/ ...

Core Viewpoint - The renewal of the exclusive agency agreement between Gaoshi Medical and Schwind eye-tech-solutions GmbH signifies a strengthened strategic partnership, enhancing Gaoshi Medical's competitive advantage in the refractive surgery equipment market in China [1] Group 1: Agreement Details - Gaoshi Medical's subsidiary, Shanghai Gaoshi Mingwang Medical Equipment Co., Ltd., has officially renewed its exclusive agency agreement with Schwind eye-tech-solutions GmbH for the Chinese market, including mainland China, Hong Kong, and Macau [1] - The partnership with Schwind, a key supplier since their initial collaboration in 2009, has lasted over 16 years, indicating a stable and long-term relationship [1] Group 2: Market Implications - The renewal of the exclusive agency agreement is crucial for consolidating Gaoshi Medical's competitive edge in the refractive surgery equipment market in China [1]

Core Viewpoint - The renewal of the exclusive agency agreement between Gaoshi Medical and Schwind eye-tech-solutions GmbH signifies a long-term strategic partnership that enhances Gaoshi Medical's competitive advantage in the refractive surgery equipment market in China [1] Group 1: Company Overview - Gaoshi Medical's subsidiary, Shanghai Gaoshi Mingwang Medical Equipment Co., Ltd., has recently renewed its exclusive agency agreement with Schwind eye-tech-solutions GmbH for the Chinese market, including mainland China, Hong Kong, and Macau [1] - The partnership with Schwind, a key supplier since 2009, has lasted over 16 years, indicating a stable and mutually beneficial relationship [1] Group 2: Industry Context - Schwind eye-tech-solutions GmbH has over 30 years of experience in developing ophthalmic refractive surgery equipment and is recognized as a global leader in excimer laser and femtosecond laser technology [1] - Schwind's products, including the ATOS personalized navigation femtosecond and AMARIS excimer series, are known for their innovation, precision, and stability, and are widely used in over 100 countries, receiving high recognition from refractive surgery professionals globally [1] - The renewal of the agency agreement is expected to deepen the cooperative relationship and create more potential growth opportunities for Gaoshi Medical, aligning with the overall interests of the company and its shareholders [1]

Core Viewpoint - The renewal of the exclusive agency agreement between GaoShi Medical and Schwind eye-tech-solutions GmbH signifies a strengthened strategic partnership, enhancing the company's competitive position in the refractive surgery equipment market in China [1] Group 1: Partnership Details - GaoShi Medical's subsidiary, Shanghai GaoShi MingWang Medical Equipment Co., Ltd., has officially renewed its exclusive agency agreement with Schwind eye-tech-solutions GmbH for the Chinese market, including mainland China, Hong Kong, and Macau [1] - The partnership with Schwind, a key supplier since 2009, has lasted over 16 years, indicating a stable and long-term collaboration [1] Group 2: Market Implications - The renewal of the exclusive agency agreement is crucial for consolidating the group's competitive advantage in the refractive surgery equipment market in China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 與德國SCHWIND公司續簽獨家代理協議 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司附屬公司上海高視明望 醫療器械有限公司於近日正式與Schwind eye-tech-solutions GmbH（「德國Schwind 公司」）續簽獨家代理協議，繼續負責中國市場（含中國大陸地區、香港特別行 政區及澳門特別行政區）的銷售、推廣及相關服務工作。德國Schwind公司作為 本公司最重要的供應商合作夥伴之一，自2009年首次合作以來雙方穩定合作已 逾16年。本次獨家代理協議的續簽，進一步彰顯雙 ...